J Exp Bot 75:11121127
Where the oral route is not deemed adequate, initial treatment similar to that for patients with pernicious anemia may be indicated depending on the severity of the deficiency
Another exciting finding is that leptin reduction may be an alternative strategy toward reversing liver fibrosis, independent of weight loss
Semaglutide (Ozempic, Wegovy): GLP-1 receptor agonist 31-amino acid peptide Position 2: Aib substitution Position 20: Lys acylated with a C18 fatty diacid via a Glu-(AEEA-AEEA) linker Position 28: Arg substitution Tirzepatide (Mounjaro, Zepbound): Dual GIP/GLP-1 receptor agonist 39-amino acid peptide: Position 2 and 13: Aib substitution Position 20: Lys acylated with a C20 fatty diacid via a Glu-(AEEA-AEEA) linker Position 30-39: Amino acid sequence from exenatide Retatrutide: Triple GLP-1/GIP/GCG receptor agonist 39-amino acid peptide: Position 2 and 20: Aib substitution Position 13: Leucine modified with an -methyl group (2-Methylleucine) Position 17: Lys acylated with a C20 fatty diacid via a Glu-(AEEA) linker Position 30-39: Amino acid sequence from exenatide Semaglutide and Tirzepatide are widely available and well-studied, while Retatrutide's long-term effectiveness and safety profile are still being investigated in clinical trials
Practical Implications for Patients For patients suffering from back pain, the potential benefits of weight loss through semaglutide are promising
Triple agonists are a new class of weight-loss medications that work by activating three different hormone receptors linked to weight and metabolism: GLP-1, GIP, and glucagon
